BCL2L1 and leukemia: Here, the effective targeting of anti-apoptotic members BCL2 and BCLX, by the use of apigenin with standard chemotherapy agents; seem to vary dependent on the type of leukaemia cell line and chemotherapy agent used, with apigenin showing a greater modulation of anti-apoptotic members in lymphoid, compared to myeloid cells.